Stock 2496 WUHAN YZY BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Wuhan YZY Biopharma Co., Ltd.

Equities

2496

CNE1000063C4

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:28 24/05/2024 BST 		5-day change 1st Jan Change
7.45 HKD 0.00% Intraday chart for Wuhan YZY Biopharma Co., Ltd. 0.00% -16.29%
02:48pm Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference MT
10:30am Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting CI

Valuation

Fiscal Period: December 2023
Capitalization 1 1,568
Enterprise Value (EV) 1 1,462
P/E ratio -7.81 x
Yield -
Capitalization / Revenue 131 x
EV / Revenue 122 x
EV / EBITDA -9.19 x
EV / FCF -21,213,809 x
FCF Yield -0%
Price to Book 12.3 x
Nbr of stocks (in thousands) 193,849
Reference price 2 8.089
Announcement Date 26/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 12.16 2.277 11.97
EBITDA 1 -125.2 -169.2 -159
EBIT 1 -132.2 -175.6 -165.4
Operating Margin -1,087.03% -7,710.89% -1,382.12%
Earnings before Tax (EBT) 1 -148.5 -188.9 -191.7
Net income 1 -148.5 -188.9 -191.7
Net margin -1,220.96% -8,294.51% -1,601.92%
EPS 2 -0.9800 -1.098 -1.036
Free Cash Flow - -92.75 -68.9
FCF margin - -4,073.3% -575.71%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 12/09/23 12/09/23 26/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 57.1 91.9 107
Leverage (Debt/EBITDA) - - -
Free Cash Flow - -92.7 -68.9
ROE (net income / shareholders' equity) - -126% -135%
ROA (Net income/ Total Assets) - -43.6% -34.2%
Assets 1 - 432.9 560.5
Book Value Per Share 2 0.9400 0.8600 0.6600
Cash Flow per Share 2 0.5500 0.8400 1.010
Capex 1 1.9 1.41 1.93
Capex / Sales 15.64% 61.97% 16.13%
Announcement Date 12/09/23 12/09/23 26/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
WUHAN YZY BIOPHARMA CO., LTD. Stock Wuhan YZY Biopharma Co., Ltd.
-16.29% 185M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 116B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.89B
ARGENX SE Stock argenx SE
-1.69% 21.58B
GENMAB A/S Stock Genmab A/S
-10.60% 18.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.96B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 16.33B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 12.02B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2496 Stock
  4. Financials Wuhan YZY Biopharma Co., Ltd.